Revelation Biosciences, Inc. (REVBW) — 10-Q Filings
All 10-Q filings from Revelation Biosciences, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Revelation Biosciences' Cash Surges Amidst Continued Losses
— Nov 6, 2025 Risk: high
REVELATION BIOSCIENCES, INC. (REVBW) reported a net loss of $6.4 million for the nine months ended September 30, 2025, a significant improvement from the $13.3 -
REVBW Narrows Q2 Loss to $1.9M Amid R&D Cuts
— Aug 8, 2025 Risk: high
REVELATION BIOSCIENCES, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net l -
Revelation Biosciences Q1 2025 10-Q Filed
— May 8, 2025 Risk: medium
Revelation Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details various financial instruments including Class F Common Stoc -
Revelation Biosciences Q3 2024 Update: Net Loss and Stock Activity
— Nov 8, 2024 Risk: medium
Revelation Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss for the nine months ended September 30, 20 -
Revelation Biosciences Files Q2 10-Q with Warrant Details
— Aug 9, 2024 Risk: medium
Revelation Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the first six months -
Revelation Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024
— May 10, 2024 Risk: low
REVELATION BIOSCIENCES, INC. (REVBW) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Revelation Biosciences, Inc. filed a 10-Q report for the peri
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX